ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Systemic Lupus Erythematosus

Duke Researchers Create a Type 1, Type 2 Lupus Disease Model

Catherine Kolonko  |  

A new disease model for lupus tackles issues with fatigue and other serious conditions that, although quite common among patients, get less attention because they fall outside classic symptoms associated with inflammation, a debilitating force behind systemic lupus erythematosus (SLE). The model features subtypes to cate­gorize two main groups of symptoms into type 1, typically…

Phase 2 Trial Results for Sjögren’s Syndrome & SLE Presented in 2nd Plenary Session at ACR Convergence 2022

  |  

PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus. Remibrutinib in Phase 2 Sjögren’s Syndrome Trial Thomas Dörner, MD, a professor of rheumatology and clinical immunology for…

Case Report: Lupus Nephritis or a Mimic?

Matthew J. Mandell, DO, Yishui Chen, MD, Prerna Rastogi, MD, PhD, & Rebecca Tuetken, MD, PhD  |  

Syphilis, an ancient disease caused by the spirochete Treponema pallidum, has been historically referred to as the great mimicker given its heterogenous presentation. Both systemic lupus erythematosus (SLE) and syphilis can have multi-systemic involve­ment. Both parvovirus B19 and syphilis have been reported to cause histologic features similar to those seen in lupus nephritis.  We present…

3 AC&R Study Summaries: MoCA Screening in SLE, Pediatric Social Disadvantages & Surgical Weight Loss Interventions

Oshrat E. Tayer-Shifman, MD; Kimberley Yuen, BSc, MD; Zahi Touma, MD, PhD, FACP, FACR; William Daniel Soulsby, MD; Aleksandra Kostic, BSE; Valia Leifer, MA; & Elena Losina, PhD, MSC  |  

MoCA as a Screening Test in SLE Assessing the utility of the Montreal Cognitive Assessment (MoCA) By Oshrat E. Tayer-Shifman, MD, Kimberley Yuen, BSc, MD, & Zahi Touma, MD, PhD, FACP, FACR Why was this study done? Cognitive impairment is a common manifestation of systemic lupus erythematosus (SLE), with a prevalence of 40% based on…

Dermatologist, Rheumatologist Discuss Refractory Cutaneous Lupus Case

Richard D. Sontheimer, MD, & Samantha C. Shapiro, MD  |  

As a dermatologist/internist with a career-long subspecialty interest in the cutaneous manifestations of the rheumatic diseases, I found the case of refractory acute cutaneous lupus by Samantha C. Shapiro, MD, in the June 2022 issue of The Rheumatologist intriguing in several ways, and I felt my perspectives on this case might provide additional educational value…

3 New Study Summaries from AC&R: Obesity in RA, CPDD Risk Factors & SLE Disparities

Joshua F. Baker, MD, MSCE; Joel Kremer, MD; Jean Lieuw, MD, MS; Alfredo Aguirre, MD; & Jinoos Yazdany, MD, MPH  |  

1) Obesity & Treatment Response in RA Obesity & response to advanced therapies in rheumatoid arthritis Why was this study done? There have been questions regarding whether certain therapies for rheumatoid arthritis (RA) are less effective in patients with obesity, particularly for tumor necrosis factor (TNF) inhibitors, because adipose tissue is known to generate TNF,…